Also categorized in Specialties - Dermatology:
The first U.S. trials in people put CRISPR to the test in 2019
x hide permanently

Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma

Medical Xpress

Cutaneous squamous cell carcinoma (cuSCC) is the second most common diagnosed malignancy in the United States, with approximately 700,000 new cases each year. Cumulative exposure to ultraviolet light is the primary environmental risk factor that leads to cuSCC. While the majority of cuSCC cases are easily managed and treated, a small percentage of patients do not respond to treatment and have poor outcomes. Researchers at Moffitt Cancer Center want to devise better therapeutic strategies for this patient population by improving their understanding of how cuSCC develops. In a new article published online ahead of print in the ...